Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous MG-7-pulsed dendritic cell vaccine

A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with the human gastric carcinoma-associated antigen MG7, with potential immunostimulatory and antineoplastic activities. Upon administration at the inguinal lymph nodes, autologous MG7-pulsed DC vaccine may stimulate the immune system to mount an anti-tumoral cytotoxic T-lymphocyte (CTL) response against MG7-expressing tumor cells, which may result in tumor cell lysis. MG7, a glycosylated protein sequence from the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), plays a key role in the development of certain tumor cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous MG7-pulsed DC vaccine
MG-7 antigen-pulsed autologous DC vaccine
MG7-DC vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search